Adverum Biotechnologies Overview
DCF fair value estimate for Adverum Biotechnologies: $-1.6.
Get informed when a big investor buys or sells
+ Follow$-1.63
Overvalued by 137.4% based on the discounted cash flow analysis.
As of the most recent data, ADVM shows a DCF fair value of $-1.6. Scroll down for historical charts and peer comparison views.
Adverum Biotechnologies's DCF reading of $-1.6 (137.4% overvalued) is a model output, not a certainty. Small changes in long-term growth or the discount rate can move fair value a lot. Treat the number as a structured starting point, then verify whether Adverum Biotechnologies's recent cash-flow history supports the assumptions.
Besides this discounted cash flow page, Stockcircle has Adverum Biotechnologies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect DCF fair value (currently $-1.6) with ownership activity and broader fundamentals.
Adverum Biotechnologies's DCF fair value is $-1.6; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
